In vitro and in vivo effects of sub-MICs of pexiganan and imipenem on pseudomonas aeruginosa adhesion and biofilm development;Effetti in vitro e in vivo di sub-mic di pexiganan e imipenem sull'adesione e sviluppo di biofilm di pseudomonas aeruginosa

Infezioni in Medicina

Volumn 21, Issue 4, 2013, Pages 287-295

  Cirioni, Oscar ^a   Silvestri, Carmela ^a   Ghiselli, Roberto ^a   Kamysz, Wojciech ^b   Minardi, Daniele ^a   Castelli, Pamela ^a   Orlando, Fiorenza ^c   Kamysz, Elzbieta ^d   Provinciali, Mauro ^c   Muzzonigro, Giovanni ^b   Guerrieri, Mario ^a   Giacometti, Andrea ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b UNIVERSITY OF GDA SK   (Poland)

^c INRCA   (Italy)

^d MEDICAL UNIVERSITY OF GDANSK   (Poland)

Author keywords

Animal model; Antimicrobial peptides; Biofilm; Imipenem; Pexiganan; Pseudomonas aeruginosa

Indexed keywords

IMIPENEM; PEXIGANAN; ANTIINFECTIVE AGENT; ANTIMICROBIAL CATIONIC PEPTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GROWTH; BACTERIUM ADHERENCE; BIOFILM; COLONY FORMING UNIT; CONTROLLED STUDY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PSEUDOMONAS AERUGINOSA; RAT; ANIMAL; DRUG EFFECTS; HUMAN; IN VITRO STUDY; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; PHYSIOLOGY; STENT; WISTAR RAT;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; BACTERIAL ADHESION; BIOFILMS; FEMALE; HUMANS; IMIPENEM; IN VITRO TECHNIQUES; MICROBIAL SENSITIVITY TESTS; PSEUDOMONAS AERUGINOSA; RATS; RATS, WISTAR; STENTS;

EID: 84891618334     PISSN: 11249390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Hancock R.E.W., Speert D.P. Antibiotic resistance in Pseudomonas aeruginosa: mechanisms and impact on treatment. Drug 3, 247-255, 2000.
2. Le Berre, R., S. Nguyen, E. Nowak, et al. Quorum-sensing activity and related virulence factor expression in clinically pathogenic isolates of Pseudomonas aeruginosa. Clin. Microbiol. Infect. 14, 337-343, 2008.
3. Talbot G.H., Bradley J., Edwards Jr J.E., Gilbert D., Scheld M., Bartlett J.G. Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Clin. Infect. Dis. 42, 657-668, 2006.
4. Trautmann M., Lepper P.M., Haller M. Ecology of Pseudomonas aeruginosa in the intensive care unit and the evolving role of water outlets as a reservoir of the organism. Am. J. Infect. Control. 33, S41-S49, 2005.
5. Veesenmeyer J.L., Hauser A.R., Lisboa T., Rello J. Pseudomonas aeruginosa virulence and therapy: evolving translational strategies. Crit. Care Med. 37, 1777-1786, 2009.
6. Costerton J.W., Stewart P.S., Greenberg E.P. Bacterial biofilm: a common cause of persistent infections. Science 284, 1318-1322, 1999.
7. Fonseca A., Sousa J.C. Effect of antibiotic-induced morphological changes on surface properties, motility and adhesion of nosocomial Pseudomonas aeruginosa strains under different physiological states. J. Appl. Microbiol. 103, 1828-1837, 2007.
8. Wozniak D.J., Keyser R. Effects of subinhibitory concentrations of macrolide antibiotics on Pseudomonas aeruginosa. Chest 125, (Suppl. 2), 62S-69S, quiz 69S, 2004.
9. Hermsen E.D., Sullivan C.J., Rotschafer J.C. Polymyxins: pharmacology, pharmacokinetics, pharmacodynamics, and clinical applications. Infect. Dis. Clin. North Am. 17, 545-562, 2003.
10. Lyczak J.B., Cannon C., Pier G.B. Establishment of Pseudomonas aeruginosa infection: lessons from a versatile opportunist. Microbes Infect. 2, 1051-1060, 2000.
11. Tateda K., Comte R., Pechere J.C., Hler K.O.T., Yamaguchi K., Van Delden C. Azithromycin inhibits quorum sensing in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 45, 1930-1933, 2001.
12. Donlan R.M., Costerton J.W. Biofilms. Survival mechanisms of clinically relevant microorganisms. Clin. Microbiol. Rev. 15, 167-193, 2002.
13. Fux C.A., Costerton J.W., Stewart P.S., Stoodley P. Survival strategies of infectious biofilm. Trends Microbiol. 13, 34-40, 2005.
14. Mah T.F., O'Toole G.A. Mechanisms of biofilm resistance to antimicrobial agents. Trends Microbiol. 9, 34-39, 2001.
15. Vlastarakos P.V., Nikolopoulos T.P., Maragoudakis P., Tzagaroulakis A., Ferekidis E. Biofilms in ear, nose, and throat infections: how important are they? Laryngoscope 117, 668-673, 2007.
16. Stewart P.S., Costerton J.W. Antibiotic resistance of bacteria biofilm. Lancet 358, 135-138, 2001.
17. Cummins J., Reen F.J., Baysse C., Mooij M.J., O'Gara F. Sub inhibitory concentrations of the cationic antimicrobial peptide colistin induce the pseudomonas quinolone signal in Pseudomonas aeruginosa. Microbiology 155, 2826-2837, 2009.
18. Kawamura-Sato K., Iinuma Y., Hasegawa T., Horii T., Yamashino T., Ohta M. Effect of subinhibitory concentrations of macrolides on expression of flagellin in Pseudomonas aeruginosa and Proteus mirabilis. Antimicrob. Agents Chemother. 44, 2869-2872, 2000.
19. Balaban N., Gov Y., Giacometti A., et al. A chimeric peptide composed of a dermaseptin derivative and an RNA III-Inhibiting peptide prevents graft-associated infections by antibiotic-resistant staphylococci. Antimicrob. Agents Chemother. 48, 2544-2550, 2004.
20. Cirioni O., Giacometti A., Ghiselli R., et al. Pretreatment of central venous catheters with the cathelicidin BMAP-28 enhances the efficacy of antistaphylococcal agents in the treatment of experimental catheter-related infection. Peptides 27, 2104-2110, 2006.
21. Cirioni O., Giacometti A., Ghiselli R., et al. Citropin 1.1-treated central venous catheters improve the efficacy of hydrophobic antibiotics in the treatment of experimental staphylococcal catheter-related infection. Peptides 27, 1210-1216, 2006.
22. Overhage J., Campisano A., Bains M., Torfs E.C.W., Rehm B.H.A, Hancock R.E.W. Human host defense peptide LL-37 prevents bacterial biofilm formation. Infect. Immun. 76, 4176-4182, 2008.
23. Giacometti A., Cirioni O., Barchiesi F., Del Prete M.S., Scalise G. Antimicrobial activity of polycationic peptides. Peptides 20, 1265-1273, 1999.
24. Orlando F., Ghiselli R., Cirioni O., et al. BMAP28 improves the efficacy of vancomycin in rat models of gram-positive cocci ureteral stent infection. Peptides 29, 1118-1123, 2008.
25. Ge Y., MacDonald D., Holroyd K.J., Thornsberry C., Wexler H., Zasloff M. In vitro antibacterial properties of pexiganan, an analog of magainin. Antimicrob. Agents Chemother. 43, 782-788, 1999.
26. Giacometti A., Cirioni O., Ghiselli R., et al. Effects of pexiganan alone and combined with betalactams in experimental endotoxic shock. Peptides 26, 207-216, 2005.
27. Lamb H.M., Wiseman L.R. Pexiganan acetate. Drugs 56, 1047-1052, 1998.
28. Zasloff M. Magainins, a class of antimicrobial peptides from Xenopus skin: isolation, characterization of two active forms, and partial cDNA sequence of a precursor. Proc. Natl. Acad. Sci. USA 84, 5449-5453, 1987.
29. Clinical and Laboratory Standards Institute (CLSI). Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically: Approved standard M7-A6. Villanova, PA. 2003.
30. Cerca N., Martins S., Pier G.B., Oliveira R., Azeredo J. The relationship between inhibition of bacterial adhesion to a solid surface by sub-MIC of antibiotics and subsequent development of a biofilm. Res. Microbiol. 156, 650-655, 2005.
31. Barros M., Martinelli R., Rocha H. Experimental supratrigonal cystectomy. Evaluation of long term complications. Int. Braz. J. Urol. 32, 350-354, 2006.
32. Balague C., Fernandez L., Perez J., Grau R. Effect of ciprofloxacin on adhesive properties of non-P mannoseresistant uropathogenic Escherichia coli isolates. J. Antimicrob. Chemother. 51, 401-404, 2003.
33. Davies J., Spiegelman G.B., Yim G. The world of subinhibitory antibiotic concentrations. Curr. Opin. Microbiol. 9, 445-453, 2006.
34. Coenye T., Nelis H.J. In vitro and in vivo model systems to study microbial biofilm formation. J. Microbiol. Methods 83, 89-105, 2010.
35. Pagani L., Landini P., Luzzaro F., Debiaggi M., Romero E. Emergence of cross-resistance to imipenem and other beta-lactam antibiotics in Pseudomonas aeruginosa during therapy. Microbiologica 13, 43-53, 1990.
36. Hall-Stoodley L., Costerton J.W., Stoodley P. Bacterial biofilms: from the natural environment to infectious diseases. Nat. Rev. Microbiol. 2, 95-108, 2004.
37. Trè-Hardy M., Vanderbist F., Traore H., Devleeschouwer M.J. In vitro activity of antibiotic combinations against Pseudomonas aeruginosa biofilm and planktonic cultures. Int. J. Antimicrob. Agents 31, 329-336, 2008.
38. Powers J.P., Hancock R.E.W. The relationship between peptide structure and antibacterial activity. Peptides 24, 1681-1691, 2003.
39. Singh P.K., Parsek M.R., Greenberg E.P., Welsh M.J. A component of innate immunity prevents bacterial biofilm development. Nature 41, 7552-7555, 2002.